Results 111 to 120 of about 10,075 (184)

COVID‐19 Vaccine Hesitancy, Self‐Reported Adverse Events, and Determinants Among Ethiopian Healthcare Professionals During COVID‐19 Pandemic

Public Health Challenges, Volume 4, Issue 3, September 2025.
Among Ethiopian HCPs, 45.6% hesitated to take the first COVID‐19 vaccine dose due to safety and efficacy concerns. Addressing these through transparent communication and religious engagement is crucial to boost vaccine uptake. ABSTRACT This nationwide cross‐sectional online survey aimed to assess coronavirus disease 2019 (COVID‐19) vaccine hesitancy ...
Alfoalem Araba Abiye, Sisay Endale, Zenebe Negash, Shemsu Umer Hussen, Dawit Teshome Gebregeorgise, Melaku Tileku Tamiru, Dessale Abate Beyene, Hana Shafi Amde, Amanuel Yishak Negash   +8 more
wiley   +1 more source

Anti‐PF4 disorders: Pathogenesis, diagnosis and treatment

British Journal of Haematology, Volume 207, Issue 3, Page 709-722, September 2025.
Anti‐platelet factor 4 (PF4) disorders include heparin‐induced thrombocytopenia (HIT) and vaccine‐induced immune thrombocytopenia and thrombosis (VITT)/VITT‐like disorders. The formation of immunoglobulin G (IgG)/PF4 immune complexes facilitates uncontrolled activation of platelets, neutrophils and monocytes via IgG‐mediated Fcγ receptor binding.
Megan V. Preece, Devi V. Pathak, Mike Laffan, Deepa J. Arachchillage   +3 more
wiley   +1 more source

Comparing ChAdOx1 nCoV-19 Coronavirus Vaccine (Recombinant) (Covishield) and BBV152; Bharat Biotech COVID-19 Vaccine (Covaxin) for COVID-19: Reports of Adverse Events Following Vaccination among the Indian Population

Indian Journal of Public Health
Background: COVID-19 is declared a global pandemic by the WHO; vaccines were the need of the hour to reduce mortality and return to some form of normal life.
Sukhpal Kaur, Latika Rohilla, Choro Athiphro Kayina, Jasvir Kaur, Gurpreet Kaur, Anjani Walia, Pramod Kumar, Ajay Singh, Sushma Saini, Shiv Lal Soni, Pankaj Malhotra   +10 more
doaj   +1 more source

Process-related impurities in the ChAdOx1 nCov-19 vaccine

, 2021
Abstract Sinus venous thrombosis has been linked to immunization with the ChAdOx1 nCov-19 vaccine. The initial trigger for this serious adverse event has not been determined. We analyzed the ChAdOx1 nCov-19 vaccine by biochemical and proteomic methods. We found that the vaccine, in addition to the adenovirus vector, contains substantial
Lea Krutzke, Reinhild Roesler, Sebastian Wiese, Stefan Kochanek   +3 more
openaire   +1 more source

COVID‐19 Vaccine Effectiveness Against Hospitalizations and Severe Outcomes in Kosovo, 2022–2024: A Test‐Negative Case–Control Study

Influenza and Other Respiratory Viruses, Volume 19, Issue 9, September 2025.
ABSTRACT Background Few studies have evaluated COVID‐19 vaccine effectiveness (VE) in middle‐income countries, particularly in eastern Europe. We aimed to estimate COVID‐19 VE against SARS‐CoV‐2‐confirmed hospitalizations and severe outcomes in Kosovo.
Besfort Kryeziu, Sandra Cohuet, Ariana Kalaveshi‐Osmani, Zana Kaçaniku‐Deva, Pranvera Kaçaniku‐Gunga, Iris Finci, Miguel Angel Sanchez, James Humphreys, Naser Ramadani, Edita Haxhiu, Kostas Danis, Angela M. C. Rose, Isme Humolli, Mark A. Katz   +13 more
wiley   +1 more source

A Quantitative Benefit–Risk Analysis of ChAdOx1 nCoV-19 Vaccine among People under 60 in Italy

, 2021
The Oxford-AstraZeneca ChAdOx1 nCoV-19 is a vaccine against the COVID-19 infection that was granted a conditional marketing authorization by the European Commission in January 2021.
Damiano De Ambrosi, De Ambrosi, Damiano, Daniele Ceriotti, Marco Farsoni, Palladino, Raffaele, De Vito, Marta, Seminara, Giuseppina, Ceriotti, Daniele, Marta De Vito, Francesco Barone-Adesi, Barone-Adesi, Francesco, Giuseppina Seminara, Raffaele Palladino, Farsoni, Marco   +13 more
core   +1 more source

Comparison of vaccine-induced immune thrombocytopenia and thrombosis cases following two adenovirus-vectored COVID-19 vaccines

Communications Medicine
Background: Vaccine-induced immune thrombocytopenia and thrombosis (VITT) was first described after administration of adenovirus-vectored COVID-19 vaccines including Ad26.COV2.S and ChAdOx1 nCoV-19.
Rian Van Rampelbergh, Sue Pavord, Luis Anaya-Velarde, Vitalija van Paassen, Karin Hardt, Emiliano Tatar, Javier Ruiz-Guiñazú, Dawn Baumgardner, Valérie Oriol Mathieu, Nicolas Praet, Hendy Kristyanto, Jerald Sadoff, Macaya Douoguih, Yimei Xu, Frank Struyf   +14 more
doaj   +1 more source

Heterologous prime–boost vaccination with ChAdOx1 nCoV-19 and BNT162b2 [PDF]

The Lancet Infectious Diseases, 2021
Tenbusch, Matthias, Schumacher, Sofie, Vogel, Emanuel, Priller, Alina, Held, Jürgen, Steininger, Philipp, Beileke, Stephanie, Irrgang, Pascal, Brockhoff, Ronja, Salmanton-García, Jon, Tinnefeld, Kathrin, Mijocevic, Hrvoje, Schober, Kilian, Bogdan, Christian, Yazici, Sarah, Knolle, Percy, Cornely, Oliver A, Überla, Klaus, Protzer, Ulrike, Roggendorf, Hedwig, Zelger, Otto, Christa, Catharina, Jeske, Samuel, Heringer, Sarah, Alsalameh, Rayya, Esse, Jan, Mattner, Jochen, Wytopil, Monika   +27 more
openaire   +3 more sources

Portal vein thrombosis associated with ChAdOx1 nCov-19 vaccination [PDF]

The Lancet Gastroenterology & Hepatology, 2021
Öcal, Osman, Stecher, Stephanie-Susanne, Wildgruber, Moritz   +2 more
openaire   +2 more sources

Factors associated with hesitancy to the second dose of ChAdOx1 nCov-19 vaccine (N = 187).

, 2021
Factors associated with hesitancy to the second dose of ChAdOx1 nCov-19 vaccine (N = 187).
Yoon Soo Park (4270357), Yong Chan Kim (4805937), Min Hyung Kim (541741), Da Ae Kim (9548730), Ju Hyun Lee (9188898), Nak-Hoon Son (11512864)   +5 more
core   +1 more source